Aldeyra Therapeutics resubmits NDA for reproxalap for DED signs and symptoms treatment
October 3rd 2024Reproxalap was previously found to be statistically superior to vehicle for the primary endpoint of ocular discomfort (P=0.004) in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial.
Study reports the majority of MiYOSMART spectacle lens users continue use for as long as 8 years
October 1st 2024By alternating the focus area—or the clear zone of the lens—and defocus area—the honeycomb-shaped segment of the lens—the spectacle lenses achieve clear vision and manage myopia progression.
EyeCon 2024: Meet the Visionary in Eye Care award recipients
September 28th 2024Three resident eye care providers—Khanh Huang, OD; Anupam Garg, MD, PhD; and Shail Patel, MD—were honored with the Visionary in Eye Care award at EyeCon 2024, which recognizes their achievements and contributions during their residency programs.
EyeCon 2024: New treatments in geographic atrophy from detection to intervention
September 28th 2024At EyeCon 2024, Dr. Adam S. Wenick led a symposium on geographic atrophy, covering diagnosis, FDA-approved treatments, and key clinician considerations through case presentations by Dr. Leonard Messner.